• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

瑞德西韦预防 2019 冠状病毒病（COVID-19）患者接受有创机械通气或死亡的疗效：自适应 COVID-19 治疗试验-1 队列数据的事后分析。

Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data.

机构信息

Division of Infectious Diseases, Penn State Health Milton S. Hershey Medical Center, Hershey, Pennsylvania, USA.

Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, Rockville, Maryland, USA.

出版信息

Clin Infect Dis. 2022 Apr 9;74(7):1260-1264. doi: 10.1093/cid/ciab695.

DOI:10.1093/cid/ciab695
PMID:34379740
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8436376/
Abstract

This post hoc analysis of the Adaptive Coronavirus Disease 2019 (COVID-19) Treatment Trial-1 (ACTT-1) shows a treatment effect of remdesivir (RDV) on progression to invasive mechanical ventilation (IMV) or death. Additionally, we create a risk profile that better predicts progression than baseline oxygen requirement alone. The highest risk group derives the greatest treatment effect from RDV.

摘要

这篇针对自适应 2019 年冠状病毒病（COVID-19）治疗试验 1（ACTT-1）的事后分析显示，瑞德西韦（RDV）对进展为有创机械通气（IMV）或死亡有治疗作用。此外，我们创建了一个风险概况，该概况比单独的基线氧需求更能预测进展。风险最高的组从 RDV 中获得的治疗效果最大。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a87/8994578/ab80e43555f1/ciab695f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a87/8994578/ab80e43555f1/ciab695f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2a87/8994578/ab80e43555f1/ciab695f0001.jpg

相似文献

1
Remdesivir for the Prevention of Invasive Mechanical Ventilation or Death in Coronavirus Disease 2019 (COVID-19): A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-1 Cohort Data.瑞德西韦预防 2019 冠状病毒病（COVID-19）患者接受有创机械通气或死亡的疗效：自适应 COVID-19 治疗试验-1 队列数据的事后分析。
Clin Infect Dis. 2022 Apr 9;74(7):1260-1264. doi: 10.1093/cid/ciab695.
2
Examining the bias-efficiency tradeoff from incorporation of nonconcurrent controls in platform trials: A simulation study example from the adaptive COVID-19 treatment trial.考察平台试验中纳入非同期对照所带来的偏倚-效率权衡：来自适应性COVID-19治疗试验的模拟研究示例
Clin Trials. 2025 Feb 8:17407745251313928. doi: 10.1177/17407745251313928.
3
Remdesivir for severe covid-19: a clinical practice guideline.瑞德西韦治疗严重 COVID-19：临床实践指南。
BMJ. 2020 Jul 30;370:m2924. doi: 10.1136/bmj.m2924.
4
Effectiveness of remdesivir in patients with COVID-19 and severe renal insufficiency: a nationwide cohort study in Japan.瑞德西韦对新冠病毒病合并严重肾功能不全患者的疗效：日本一项全国性队列研究
Infect Dis (Lond). 2025 Feb;57(2):192-201. doi: 10.1080/23744235.2024.2409729. Epub 2024 Oct 6.
5
Safety evaluation of remdesivir administration in patients with severe renal impairment and coronavirus disease: a systematic review and meta-analysis.重度肾功能损害患者使用瑞德西韦治疗冠状病毒病的安全性评估：一项系统评价和荟萃分析。
BMC Infect Dis. 2025 Jun 2;25(1):782. doi: 10.1186/s12879-025-11153-5.
6
A Systematic Review and Meta-analysis of the Effectiveness of Remdesivir to Treat SARS-CoV-2 in Hospitalized Patients: Have the Guidelines Evolved With the Evidence?一项关于瑞德西韦治疗住院的2019冠状病毒病患者有效性的系统评价和荟萃分析：指南是否随着证据的变化而演变？
Clin Infect Dis. 2025 Aug 1;81(1):20-29. doi: 10.1093/cid/ciaf111.
7
Remdesivir for the treatment of COVID-19.瑞德西韦用于治疗新型冠状病毒肺炎。
Cochrane Database Syst Rev. 2021 Aug 5;8(8):CD014962. doi: 10.1002/14651858.CD014962.
8
Remdesivir for the treatment of COVID-19.瑞德西韦治疗 COVID-19。
Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
9
Cardiac adverse events associated with remdesivir in COVID-19 patients: a systematic review and meta-analysis of randomised controlled trials.新冠患者中与瑞德西韦相关的心脏不良事件：随机对照试验的系统评价和荟萃分析
BMJ Open. 2025 Jul 18;15(7):e089977. doi: 10.1136/bmjopen-2024-089977.
10
Drug treatments for covid-19: living systematic review and network meta-analysis.Covid-19 的药物治疗：系统评价和网络荟萃分析。
BMJ. 2020 Jul 30;370:m2980. doi: 10.1136/bmj.m2980.

引用本文的文献

1
Blood absolute lymphocyte count and trajectory are important in understanding severe COVID-19.血液绝对淋巴细胞计数及其变化轨迹对于理解重症新型冠状病毒肺炎至关重要。
BMC Infect Dis. 2025 Jan 15;25(1):67. doi: 10.1186/s12879-024-10428-7.
2
SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.SARS-CoV-2 病毒 RNA 和核衣壳抗原是与严重疾病结局相关的血液生物标志物，瑞德西韦治疗后可改善这些标志物。
J Infect Dis. 2024 Sep 23;230(3):624-634. doi: 10.1093/infdis/jiae198.
3
Personalized Assessment of Mortality Risk and Hospital Stay Duration in Hospitalized Patients with COVID-19 Treated with Remdesivir: A Machine Learning Approach.

本文引用的文献

1
A neutrophil activation signature predicts critical illness and mortality in COVID-19.中性粒细胞激活特征可预测 COVID-19 患者的重症和死亡风险。
Blood Adv. 2021 Mar 9;5(5):1164-1177. doi: 10.1182/bloodadvances.2020003568.
2
Lymphopenia as a Biological Predictor of Outcomes in COVID-19 Patients: A Nationwide Cohort Study.淋巴细胞减少作为COVID-19患者预后的生物学预测指标：一项全国性队列研究。
Cancers (Basel). 2021 Jan 26;13(3):471. doi: 10.3390/cancers13030471.
3
The prognostic value of general laboratory testing in patients with COVID-19.
使用瑞德西韦治疗的COVID-19住院患者死亡率风险和住院时间的个性化评估：一种机器学习方法
J Clin Med. 2024 Mar 22;13(7):1837. doi: 10.3390/jcm13071837.
4
A Risk Profile Using Simple Hematologic Parameters to Assess Benefits From Baricitinib in Patients Hospitalized With COVID-19: A Post Hoc Analysis of the Adaptive COVID-19 Treatment Trial-2.使用简单血液学参数评估 COVID-19 住院患者使用巴瑞替尼获益的风险概况：适应性 COVID-19 治疗试验-2 的事后分析。
Ann Intern Med. 2024 Mar;177(3):343-352. doi: 10.7326/M23-2593. Epub 2024 Feb 27.
5
Remdesivir: A Review in COVID-19.瑞德西韦：在 COVID-19 中的综述。
Drugs. 2023 Sep;83(13):1215-1237. doi: 10.1007/s40265-023-01926-0. Epub 2023 Aug 17.
6
Correlates of Coronavirus Disease 2019 Inpatient Mortality at a Southern California Community Hospital With a Predominantly Hispanic/Latino Adult Population.南加州一家以西班牙裔/拉丁裔成年人口为主的社区医院中2019冠状病毒病住院死亡率的相关因素。
Open Forum Infect Dis. 2023 Jan 10;10(1):ofad011. doi: 10.1093/ofid/ofad011. eCollection 2023 Jan.
7
Remdesivir for the treatment of COVID-19.瑞德西韦治疗 COVID-19。
Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
8
COVID-19 and antimicrobial resistance: A cross-study.新型冠状病毒肺炎与抗菌药物耐药性：一项跨研究分析。
Sci Total Environ. 2022 Feb 10;807(Pt 2):150873. doi: 10.1016/j.scitotenv.2021.150873. Epub 2021 Oct 8.
9
Remdesivir, on the road to DisCoVeRy.瑞德西韦，探索之路上。
Lancet Infect Dis. 2022 Feb;22(2):153-155. doi: 10.1016/S1473-3099(21)00559-4. Epub 2021 Sep 14.
新型冠状病毒肺炎患者一般实验室检查的预后价值。
J Clin Lab Anal. 2021 Feb;35(2):e23668. doi: 10.1002/jcla.23668. Epub 2020 Dec 13.
4
Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results.用于治疗新冠肺炎的抗病毒药物 repurposed - 世界卫生组织团结试验中期结果
N Engl J Med. 2021 Feb 11;384(6):497-511. doi: 10.1056/NEJMoa2023184. Epub 2020 Dec 2.
5
Haematological characteristics and risk factors in the classification and prognosis evaluation of COVID-19: a retrospective cohort study.新冠病毒肺炎分类及预后评估中的血液学特征与危险因素：一项回顾性队列研究
Lancet Haematol. 2020 Sep;7(9):e671-e678. doi: 10.1016/S2352-3026(20)30217-9. Epub 2020 Jul 10.
6
Remdesivir for the Treatment of Covid-19 - Preliminary Report. Reply.瑞德西韦治疗新冠病毒病-初步报告。回复。
N Engl J Med. 2020 Sep 3;383(10):994. doi: 10.1056/NEJMc2022236. Epub 2020 Jul 10.
7
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.美国传染病学会关于2019冠状病毒病患者治疗与管理的指南
Clin Infect Dis. 2020 Apr 27. doi: 10.1093/cid/ciaa478.
8
Practical recommendations for reporting Fine-Gray model analyses for competing risk data.关于报告竞争风险数据的Fine-Gray模型分析的实用建议。
Stat Med. 2017 Nov 30;36(27):4391-4400. doi: 10.1002/sim.7501. Epub 2017 Sep 15.